Article Text

Download PDFPDF

Neurodevelopmental delay in normocephalic children with in utero exposure to Zika virus
  1. Adriana Virginia Faiçal1,
  2. Juliana Cabral de Oliveira2,
  3. João Vitor Vieira Oliveira2,
  4. Breno Lima de Almeida2,
  5. Iluska Andrade Agra1,
  6. Luiz Carlos Junior Alcantara2,
  7. Angelina Xavier Acosta1,
  8. Isadora Cristina de Siqueira2
  1. 1 School of Medicine - Department of Pediatrics, Federal University of Bahia, Salvador, Bahia, Brazil
  2. 2 Gonçalo Moniz Institute, Oswaldo Cruz Fundation, Salvador, Bahia, Brazil
  1. Correspondence to Dr Isadora Cristina de Siqueira, Instituto Gonçalo Moniz, Fiocruz Bahia, Salvador 40296-710, Bahia, Brazil; isadora.siqueira{at}bahia.fiocruz.br

Abstract

Neurodevelopment in 29 normocephalic children with in utero exposure to Zika virus (ZIKV) was evaluated by the Bayley Scales of Infant and Toddler Development-Third Edition. Ten (35%) infants presented neurodevelopment delay. Language, cognitive and motor delays were identified in 9 (31%), 4 (14%) and 1 (3%) infants, respectively. Children exposed to ZIKV in utero must undergo careful evaluations for the early detection of any neurodevelopment delays in order to implement prompt intervention.

  • congenital infection
  • neurodevelopment
  • Bayley-III
  • Zika virus

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • AXA and ICdS contributed equally.

  • Contributors ICdS, AXA and LCJA contributed to study design, writing of the manuscript and data analysis. AVF, JCdO, JVVO, BLdA and IAA contributed to the enrolment of participants in the study, reviewed the medical records and clinical evaluations.

  • Funding CNPq-National Council for Scientific and Technological Development (443875/2018-9) and PPSUS/BA-FAPESB003/2017/SESAB/CNPq/MS (5125/2017).

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Ethical approval This study was approved by the Institutional Review Board of the Oswaldo Cruz Foundation (IGM-FIOCRUZ) (protocol number 1.935.854/2016).

  • Provenance and peer review Not commissioned; externally peer reviewed.